Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
ObjectiveAnakinra has been increasingly used in off-label indications as well as dosing and mode of administration in a variety of inflammatory conditions. We aimed to review our clinical practice and compare treatment outcomes with published data.MethodsClinical data from electronic records were re...
Saved in:
Main Authors: | Šárka Fingerhutová (Author), Eva Jančová (Author), Pavla Doležalová (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anakinra and hepatotoxicity in pediatric rheumatology: a case series
by: Frederico Rajão Martins, et al.
Published: (2023) -
Educational initiatives and training for paediatric rheumatology in Europe
by: Helen E. Foster, et al.
Published: (2018) -
Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy
by: A Aiello, et al.
Published: (2023) -
How Safe Are Biological Agents in Pediatric Rheumatology?
by: Emine Nur Sunar Yayla, et al.
Published: (2024) -
Familial mediterranean fever and pauciimmune renal vasculitis: the role of IL-1 blockade (Anakinra)
by: Sánchez A, et al.
Published: (2011)